Citations

Mayo Clinic

Clear

2 citation(s) found for "Eber, G".

C16-03 The Warden as Surrogate: Statutes, Policies and Regulations Governing Decision-Making for Incapacitated Incarcerated Patients Across the United States
Demartino, E S, Shelby, S, Weglarz, S, Eber, G, Agam, P, Meyer, L, Nguyen, N V, Kaiksow, F, Sulmasy, D, White, D B, Tilburt, J, Williams, B, DeMartino, Erin S. , Eber, Gabriel B. , Meyer, Leigh , Nguyen, N.V. , Kaiksow, Farah Acher , Sulmasy, Daniel P., White, Douglas B. , Tilburt, Jon C.

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.990 Get It

Abstract Rationale The United States has the highest per capita incarceration rate of any developed democracy. As the incarcerated population ages, medically complex and frail patients are increasingly hospitalized in the community, often arriving without decisional capacity and with limited family involvement. This is the first analysis of state laws and policies governing decision-making for incapacitated incarcerated patients. Methods Two team members independently conducted Westlaw and Internet searches for statutes, regulations and department of corrections (DOC) policies from 50 states and the District of Columbia, identifying language about medical decision-making for incapacitated incarcerated patients. These parallel searches were merged into a single database and reviewed by the analytic team, who created a codebook of inductively and deductively derived themes, guided by principles of grounded theory. The codebook was then systematically applied to the database by 2 independent coders; all data were double-coded. Disputes were resolved by consensus with the entire analytic team, in consultation with a legal scholar. Results Thirty-four of 51 jurisdictions have language addressing decision-making for incapacitated incarcerated patients. Data collected include the definition and determination of incapacity, language affirming incarcerated persons’ right to autonomy in medical decision-making, approaches to decision-making for patients with and without surrogate decision-makers, and whether treatment over patient/surrogate objection is authorized. Assertions about the importance of advance care planning (n = 25) are often undercut by procedural hurdles (n = 20), such as complex witnessing requirements for advance directive completion. Many jurisdictions (n = 26) allow family or friends to serve as legally recognized decision-makers. Thirteen jurisdictions exclude an incarcerated person from serving as decision-maker for another incarcerated person. Fourteen jurisdictions have provisions allowing for treatment over the objection of a patient or their surrogate. While approaches to unrepresented patients differ widely (Figure), 5 jurisdictions grant narrow decisional authority to treating physicians and 4 jurisdictions authorize correctional employees to make medical decisions. Conclusion A heterogeneous assortment of laws, policies and regulations govern the care of incapacitated incarcerated patients, with wide variation observed from jurisdiction to jurisdiction. One-third of jurisdictions lack policies or language regarding decision-making processes for incapacitated incarcerated patients. Even more troubling, 14 jurisdictions allow treatment over a patient or surrogate’s objection and 4 jurisdictions delegate authority over decisions for unrepresented patients to correctional employees, such as the prison medical director or the warden. These findings raise serious concerns about autonomy, beneficence and justice. National reform is needed to align correctional policies with established ethical standards for surrogate decision-making. This abstract is funded by: National Institute on Aging
Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency
Bianchi, Paola , Fermo, Elisa , Glader, Bertil , Kanno, Hitoshi , Agarwal, Archana M. , Barcellini, Wilma , Eber, Stefan , Hoyer, James D., Kuter, David J. , Maia, Tabita , Mañú‐Pereira, María del Mar, Kalfa, Theodosia A. , Pissard, Serge , Segovia, José C. , Beers, Eduard J. van , Gallagher, Patrick G. , Rees, David C. , Wijk, Richard van , Diseases, with the endorsement of EuroBloodNet, the European Reference Network in Rare Hematological, Agarwal, Archana , van Beers, Eduard , Kuter, David J. , Diseases, with the endorsement of EuroBloodNet, the European Reference Network in Rare Hematological

American Journal of Hematology | October 25, 2018 | Volume: 94 | Issue: 1 | Pages: 149-161

10.1002/ajh.25325 | PMID 30358897 Get It

Abstract Pyruvate kinase deficiency (PKD) is the most common enzyme defect of glycolysis and an important cause of hereditary, nonspherocytic hemolytic anemia. The disease has a worldwide geographical distribution but there are no verified data regarding its frequency. Difficulties in the diagnostic workflow and interpretation of PK enzyme assay likely play a role. By the creation of a global PKD International Working Group in 2016, involving 24 experts from 20 Centers of Expertise we studied the current gaps in the diagnosis of PKD in order to establish diagnostic guidelines. By means of a detailed survey and subsequent discussions, multiple aspects of the diagnosis of PKD were evaluated and discussed by members of Expert Centers from Europe, USA, and Asia directly involved in diagnosis. Broad consensus was reached among the Centers on many clinical and technical aspects of the diagnosis of PKD. The results of this study are here presented as recommendations for the diagnosis of PKD and used to prepare a diagnostic algorithm. This information might be helpful for other Centers to deliver timely and appropriate diagnosis and to increase awareness in PKD.